Factor IX complex is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. It may also be used in those with not enough of these factors due to other reasons such as warfarin therapy. It is given by slow injection into a vein.

The global Lyophilized Prothrombin Complex market size is projected to grow from US$ 1029 million in 2024 to US$ 2081 million in 2030; it is expected to grow at a CAGR of 12.4% from 2024 to 2030.

ReportPrime's newest research report, the “Lyophilized Prothrombin Complex Industry Forecast” looks at past sales and reviews total world Lyophilized Prothrombin Complex sales in 2023, providing a comprehensive analysis by region and market sector of projected Lyophilized Prothrombin Complex sales for 2024 through 2030.

This Insight Report provides a comprehensive analysis of the global Lyophilized Prothrombin Complex landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

This report also analyzes the strategies of leading global companies with a focus on Lyophilized Prothrombin Complex portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lyophilized Prothrombin Complex market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lyophilized Prothrombin Complex and breaks down the forecast by:

1. Type
2. Application
3. Geography
4. Market size

United States market for Lyophilized Prothrombin Complex is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Lyophilized Prothrombin Complex is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Lyophilized Prothrombin Complex is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Lyophilized Prothrombin Complex players cover:

• CSL Behring
• Grifols
• Octapharma
• Prothya Biosolutions
• Takeda

This report presents a comprehensive overview, market shares, and growth opportunities of Lyophilized Prothrombin Complex market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Beriplex
• Profilnine
• Octaplex
• Prothromplex
• Cofact
• Other

Segmentation by Application:

• Hemophilia B
• Acquired Coagulation Factor Deficiency

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration:

• CSL Behring
• Grifols
• Octapharma
• Prothya Biosolutions
• Takeda

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Lyophilized Prothrombin Complex market?
2. What factors are driving Lyophilized Prothrombin Complex market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Lyophilized Prothrombin Complex market opportunities vary by end market size?
5. How does Lyophilized Prothrombin Complex break out by Type, by Application?